News

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills
The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...
Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases
Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise ...
Novo Nordisk, Septerna sign $2.2B deal to develop weight-loss pill
Pharmaceutical giant Novo Nordisk (NVO) inks a $2.2 billion deal with biotech company Septerna (SEPN) to develop a GLP-1 ...
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs
Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...
Zacks Investment Research on MSN4h
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...
Novo Nordisk in pact with Septerna for oral obesity drugs
Septerna (SEPN) stock surges as Novo Nordisk (NVO) inks $2.2B deal to develop and commercialize oral obesity drugs. Read more ...
Contract Pharma2h
Novo Nordisk Invests $2.2B in Septerna’s Oral Drugs
Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...
Fierce Biotech1d
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...
STAT1d
Novo Nordisk strikes deal with Septerna to develop obesity pills
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
Septerna stock soars on Novo Nordisk collaboration
Under the agreement, Septerna could receive up to approximately $2.2 billion, including over $200 million in upfront and near-term milestone payments. Additionally, Septerna will be eligible for ...